Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Leaning into high-quality, economically resilient health care and industrial compounders while trimming consumer cyclical exposure amid rising interest rates and elevated energy prices.
Full Quick Take
Leaning into high-quality, economically resilient health care and industrial compounders while trimming consumer cyclical exposure amid rising interest rates and elevated energy prices.
Cautious on elevated broad-market valuations and rising rate pressures, leaning into high-quality healthcare and industrials while initiating longs in $GNRC, $RIG, and $ESAB.
Full Quick Take
Cautious on elevated broad-market valuations and rising rate pressures, leaning into high-quality healthcare and industrials while initiating longs in $GNRC, $RIG, and $ESAB.
Driven by a cyclical rebound across overweight life sciences tools holdings, while initiating turnaround stakes in Biogen and Humana and exiting 14 positions.
Full Quick Take
Driven by a cyclical rebound across overweight life sciences tools holdings, while initiating turnaround stakes in Biogen and Humana and exiting 14 positions.
Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences.
Full Quick Take
Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences.
Outperforming on strong semiconductor and biotech stock selection. Health care outperformed the sector by 16 percentage points driven by biotech holdings.
Full Quick Take
Outperforming on strong semiconductor and biotech stock selection. Health care outperformed the sector by 16 percentage points driven by biotech holdings.
McIntyre concentrated over 20% in QDEL at $11, viewing it as a once-in-a-decade opportunity. Five temporary issues mask a stable diagnostics business with 95% contract renewal rates and 6% core growth.
Full Quick Take
McIntyre concentrated over 20% in QDEL at $11, viewing it as a once-in-a-decade opportunity. Five temporary issues mask a stable diagnostics business with 95% contract renewal rates and 6% core growth.
Alger Small Cap Focus Fund outperformed its benchmark in Q4 2025, propelled by strong results and M&A tailwinds within its molecular diagnostics holdings, despite volatility in its AI infrastructure and biotech positions.
Full Quick Take
Alger Small Cap Focus Fund outperformed its benchmark in Q4 2025, propelled by strong results and M&A tailwinds within its molecular diagnostics holdings, despite volatility in its AI infrastructure and biotech positions.
Small-cap growth manager outperformed benchmarks with +18-25% Q3 returns, focusing on healthcare companies with new products and large market opportunities.
Full Quick Take
Small-cap growth manager outperformed benchmarks with +18-25% Q3 returns, focusing on healthcare companies with new products and large market opportunities.
Trailing its benchmark's 4.83% gain due to headwinds in key healthcare and financial holdings, despite strong gains from AI-exposed semiconductor holdings.
Full Quick Take
Trailing its benchmark's 4.83% gain due to headwinds in key healthcare and financial holdings, despite strong gains from AI-exposed semiconductor holdings.
KCM Small Cap Growth outperformed by 207bps in Q2 2025 despite tariff volatility, led by digital advertising and diagnostics holdings. Strong earnings season expected while trade policy and Fed decisions create uncertainty.
Full Quick Take
KCM Small Cap Growth outperformed by 207bps in Q2 2025 despite tariff volatility, led by digital advertising and diagnostics holdings. Strong earnings season expected while trade policy and Fed decisions create uncertainty.
Underperforming its benchmark due to a market environment that favored high-beta, riskier stocks. However, the fund maintains robust portfolio fundamentals and continues to focus on high-quality compounders with durable competitive advantages.
Full Quick Take
Underperforming its benchmark due to a market environment that favored high-beta, riskier stocks. However, the fund maintains robust portfolio fundamentals and continues to focus on high-quality compounders with durable competitive advantages.
Baron Discovery Fund outperformed during Q1 2025 market decline driven by tariff concerns. The fund's investing in reverse strategy positions it to capitalize on market dislocations by purchasing high-quality, fast-growing companies at attractive valuations.
Full Quick Take
Baron Discovery Fund outperformed during Q1 2025 market decline driven by tariff concerns. The fund's investing in reverse strategy positions it to capitalize on market dislocations by purchasing high-quality, fast-growing companies at attractive valuations.
Underperforming its benchmark amid tariff uncertainty and small-cap underperformance. The strategy's defensive positioning and valuation discipline provided some downside protection while healthcare holdings faced mixed results.
Full Quick Take
Underperforming its benchmark amid tariff uncertainty and small-cap underperformance. The strategy's defensive positioning and valuation discipline provided some downside protection while healthcare holdings faced mixed results.
Spree Capital initiated Danaher based on an underappreciated transformation into a life sciences powerhouse with 80% recurring revenues. COVID expanded the molecular diagnostics installed base by 250%, creating a strengthened razor-and-blade model.
Full Quick Take
Spree Capital initiated Danaher based on an underappreciated transformation into a life sciences powerhouse with 80% recurring revenues. COVID expanded the molecular diagnostics installed base by 250%, creating a strengthened razor-and-blade model.